Across TCGA pan-cancer cohorts, GPRIN3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GPRIN3 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GPRIN3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GPRIN3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where GPRIN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.715	0.381	.012	9	view →
CCRCC	DFS	Tertile	IV	0.908	0.162	.024	8	view →
GBM	OS	Tertile	All	0.300	0.550	.029	4	view →
LUAD	OS	Quartile	II,III,IV	0.871	1.000	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: GPRIN3 tumor-vs-normal RNA expression · all GPRIN3 data types